Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKU (Prism302)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01889862
Recruitment Status : Active, not recruiting
First Posted : July 1, 2013
Last Update Posted : December 27, 2017
Information provided by (Responsible Party):
BioMarin Pharmaceutical

Brief Summary:
The BMN 165 clinical development program has been designed to demonstrate the safety and efficacy of BMN 165 in reducing blood Phe concentrations in adults with PKU.

Condition or disease Intervention/treatment Phase
Phenylketonuria (PKU) Drug: BMN165 20mg/day Drug: BMN165 40mg/day Drug: Placebo Phase 3

Detailed Description:

165-302 is a Phase 3, 4 Part, Randomized, Double-Blind, Placebo-Controlled, Discontinuation Study to Evaluate the Efficacy and Safety of Self Administered Subcutaneous Injections of BMN 165 by Adults With PKU.

This study is open only to adults who have been exposed to BMN165 in a previous study.

Study BMN 165-302 is a four-part, Phase 3 study.

  • PART 1: Open-label period
  • PART 2: A Randomized, double-blind, placebo-controlled period of 8 weeks
  • PART 3: PK (plasma BMN 165) and PD (plasma Phe) assessment.
  • Part 4: A long-term, open-label extension study.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 250 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Four-Part, Phase 3, Randomized, Double-Blind, Placebo- Controlled, Four-Arm, Discontinuation Study to Evaluate the Efficacy and Safety of Subcutaneous Injections of BMN 165 Self-Administered by Adults With Phenylketonuria (PKU)
Actual Study Start Date : July 29, 2013
Actual Primary Completion Date : January 13, 2016
Estimated Study Completion Date : March 31, 2019

Arm Intervention/treatment
Active Comparator: BMN165 20mg/day
BMN165 20mg/day self-administered daily
Drug: BMN165 20mg/day
Two different doses of BMN165 compared to each other and compared to placebo
Other Name: PEG-PAL

Placebo Comparator: Low Placebo
Low Placebo self-administered daily
Drug: Placebo
Two different doses of BMN165 compared to each other and compared to placebo
Other Name: Dextran 40

Active Comparator: BMN165 40mg/day
BMN165 40mg/day self-administered daily
Drug: BMN165 40mg/day
Two different doses of BMN165 compared to each other and compared to placebo
Other Name: PEG-PAL

Placebo Comparator: High Placebo
High Placebo self-administered daily
Drug: Placebo
Two different doses of BMN165 compared to each other and compared to placebo
Other Name: Dextran 40

Primary Outcome Measures :
  1. Incidence of adverse events experienced by subjects. [ Time Frame: Weekly throughout study. ]
    Subjects will be assessed weekly for adverse events, including laboratory abnormalities.

Secondary Outcome Measures :
  1. Cognitive and mood symptoms BMN 165 [ Time Frame: Throughout the study ]
    ADHD-RS IV and the POMS (Profile of Mood States) will be used to evaluate cognitive and mood symptoms.

  2. Plasma Phenylalanine (phe) levels [ Time Frame: Throughout the study ]

Other Outcome Measures:
  1. Protein intake as reported by subjects in diet diary [ Time Frame: Every 4 weeks, an expected average of 3 years ]
    Diet diary collected monthly to assess protein intake from medical food and from natural protein.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


Individuals eligible to participate in this study must meet all of the following criteria:

  • Have completed a prior BMN 165 study (PAL-003 or 165-301) prior to screening
  • Have had a stable BMN 165 dose regimen for at least 14 days prior to screening
  • Are at least 18 y/o and no older than 70 y/o at screening

    • Subjects who are < 18 y/o and are already enrolled into Study 165-301 under Amendment #1 (10JAN2014) may enroll into this study
  • Has identified a person who is ≥ 18 y/o who has the neurocognitive and linguistic capacities to comprehend and complete the POMS-Observer rated scale
  • Has identified a competent person(s) ≥ 18 y/o who can observe the subject during study drug administration at certain points in the study

    • A home healthcare nurse may perform the study drug observations
  • Are willing and able to provide written, signed informed consent after the nature of the study has been explained and prior to any research-related procedures; for minors, parent or guardian provides written consent and assent may be requested
  • Are willing and able to comply with all study procedures
  • For females of childbearing potential, a negative pregnancy test at screening and willing to have additional pregnancy tests during the study
  • If sexually active, willing to use two acceptable methods of contraception during and for 4 weeks after the study

    • Males post vasectomy for 2 years with no known pregnancies do not need to use any other forms of contraception during the study.
    • Females who have been in menopause for at least 2 years, have had a tubal ligation at least 1 year prior to screening, or have had a total hysterectomy do not need to use any other forms of contraception during the study.
  • Have received documented approval from a study dietitian confirming that the subject is capable of maintaining their diet
  • Have neurocognitive and linguistic capacities to comprehend and answer investigator's prompts for the ADHD-RS Investigator rated instrument and to complete the POMS-Subject rated scale
  • If applicable, maintained stable dose of medication for ADHD, depression, anxiety, or other psychiatric disorder ≥8 weeks prior to enrollment and willing to maintain stable dose throughout study unless a change is medically indicated
  • General good health, as evidenced by physical examination, clinical laboratory evaluations, and ECG tests at screening

Exclusion Criteria

Individuals who meet any of the following exclusion criteria will not be eligible to participate in the study:

  • Use of any investigational product (except BMN 165) or investigational medical device within 30 days prior to screening or requirement for any investigational agent prior to completion of all scheduled study assessments
  • Use of any medication (except BMN 165) intended to treat PKU, including the use of large neutral amino acids, within 2 days prior to the administration of study drug
  • Have known hypersensitivity to Dextran® or components of Dextran
  • Use or planned use of any injectable drugs containing PEG (except for BMN 165), including medroxyprogesterone injection, within 3 months prior to screening and during study participation
  • Current use of levodopa
  • A positive test for HIV antibody, hepatitis B surface antigen, or hepatitis C antibody
  • A history of organ transplantation or taking chronic immunosuppressive therapy
  • A history of substance abuse in the past 12 months or current alcohol or drug abuse
  • Current participation in the Kuvan registry study (PKUDOS). Patients may discontinue the PKUDOS registry trial to allow enrollment in this study
  • Pregnant or breastfeeding at screening or planning to become pregnant (self or partner) or breastfeed at any time during the study
  • Concurrent disease or condition that would interfere with study participation or safety.
  • Major surgery planned during the study period
  • Any condition that in the view of the investigator, places the subject at high risk of poor treatment compliance or terminating early from the study
  • ALT concentration at least 2x the upper limit of normal
  • Creatinine at least 1.5x the upper limit of normal

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01889862

  Hide Study Locations
United States, California
University of California, San Diego School of Medicine
La Jolla, California, United States, 92103
Children's Hospital and Research Center
Oakland, California, United States, 94609
United States, Colorado
The Children's Hospital
Aurora, Colorado, United States, 80045
United States, Florida
University of Florida
Gainesville, Florida, United States, 32610
University of South Florida
Tampa, Florida, United States, 30606
United States, Georgia
Emory Universty
Decatur, Georgia, United States, 30033
United States, Illinois
Ann and Robert H Lurie Children's Hospital
Chicago, Illinois, United States, 60614
United States, Indiana
Riley Children's Hospital
Indianapolis, Indiana, United States, 46202
United States, Kentucky
University of Kentucky
Lexington, Kentucky, United States, 40536
University of Louisville, Kosair Charities Pediatric Clinical Research Unit
Louisville, Kentucky, United States, 40202
United States, Massachusetts
Children's Hospital Boston
Boston, Massachusetts, United States, 02115
United States, Michigan
Wayne State University
Detroit, Michigan, United States, 48201
United States, Missouri
University of Missouri
Columbia, Missouri, United States, 65212
Washington University Center for Applied Research Sciences
Saint Louis, Missouri, United States, 63110
United States, Nebraska
Nebraska Medical Center
Omaha, Nebraska, United States, 68198
United States, New Jersey
Cooper Health Systems
Camden, New Jersey, United States, 08103
Atlantic Health System - Morristown Medical Center
Morristown, New Jersey, United States, 07960
United States, New York
Albany Medical Center
Albany, New York, United States, 12208
Mount Sinai Medical Center
New York, New York, United States, 10029
University of Rochester
Rochester, New York, United States, 14642
United States, Oklahoma
University of Oklahoma
Oklahoma City, Oklahoma, United States, 73140
United States, Oregon
Oregon Health and Science University
Portland, Oregon, United States, 97239
United States, Pennsylvania
St. Christopher's Hospital for Children
Philadelphia, Pennsylvania, United States, 19134
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15213
United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232
United States, Texas
University of Texas Houston Medical School
Houston, Texas, United States, 77030
United States, Utah
University of Utah Hospital
Salt Lake City, Utah, United States, 84132
United States, Wisconsin
Children's Hospital of Wisconsin
Milwaukee, Wisconsin, United States, 53226
Sponsors and Collaborators
BioMarin Pharmaceutical
Study Director: Markus Merilainen, MD BioMarin Pharmaceutical

Additional Information:
Responsible Party: BioMarin Pharmaceutical Identifier: NCT01889862     History of Changes
Other Study ID Numbers: 165-302
First Posted: July 1, 2013    Key Record Dates
Last Update Posted: December 27, 2017
Last Verified: December 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by BioMarin Pharmaceutical:

Additional relevant MeSH terms:
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Amino Acid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Metabolic Diseases